進行性尿路性器癌に対するCis-diamminedichloroplatinumの治療経験

Abstract

A trial ofcis-diamminedichloroplatinum (CDDP) has been performed at a dose of 14 to 23 mg/m2 in 9 patients with an advanced measurable genitourinary carcinoma, including 6 patients with nonseminomatous testicular tumor, 2 with urothelial tumor and I with prostatic carcinoma. 1) Two protocols were used for 6 testicular tumors; 3 patients received a single administration of CDDP, and 3 patientsreceived a combination chemotherapy with CDDP, bleomycin and vincristine. A complete remission was achieved in 2 of the 6 patients. A partial remission was obtained in 3 patients. The collective response was elicited in 83% of the patients (5 of 6). The 2 complete responders were seen in the combined chemotherapy, and they are free of disease for 11 and 21.4 months. 2) Three patients (2 urothelial tumors and 1 prostatic carcinoma) received the single administration of CDDP for 5 consecutive days every 3 weeks for 3 courses. There were partial remissions in 2 urothelial tumors for 4 and 7 months, but no response was seen in the prostatic carcinoma patient. 3) Despite of substantial gastrointestinal, mild renal toxicity and others, the chemotherapy was manageable in all patients. CDDP appears to be consistently useful in a chemotherapy model for genitourinary carcinomas, particularly testicular tumors.